MBX Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-22.1%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
-$3.11next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| 12-Week MAD Phase 1 Data for MBX 4291 in Obesity | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Phase 3 Canvuparatide Trial Initiation QuarterlyTarget: Initiation of pivotal Phase 3 trial in chronic hypoparathyroidism (HP) with ~160 patients randomized 3:1
MBX 4291 Phase 1 12-Week MAD Data QuarterlyTarget: Report 12-week multiple ascending dose (MAD) safety, tolerability, and PK/PD data in obesity
Cash Runway Quarterly440MTarget: Maintain sufficient capital reserves to fund operations into 2029
Watch Items
- Canvuparatide Phase 3 Trial Enrollment ProgressTrigger: Slower-than-expected enrollment of the planned ~160 patientsAction: Re-evaluate clinical site selection, expand geographic reach of trial sites, or adjust patient outreach strategies.
- Obesity Portfolio Candidate NominationsTrigger: Delay in nominating the amycretin prodrug (MBX 5765) or the GLP-1/GIP/GCGR triple-agonist prodrug beyond 2026Action: Review preclinical IND-enabling study timelines and allocate additional R&D resources to accelerate lead optimization.
Research as of 20 Jun 2026